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Poster Session-I 41misfold, form fibrils and deposit in vital organs causing malfunction
and death. HDM/SCT can produce hematologic remissions and
prolong survival. HDM/SCT was developed for the treatment of
AL at BostonUniversityMedical Center in 1994. In 1996, treatment
was moved to the outpatient setting. The program has been FACT-
accredited since 2000. To date, we have performed 496 SCTs. 95%
of patients are offered outpatient treatment. While patients with se-
vere cardiac involvement are not candidates forHDM/SCT, patients
with less severe cardiac disease can undergo HDM/SCT, with inpa-
tient cardiac monitoring. The CP begins with an extensive multidis-
ciplinary team evaluation involving members from hematology,
nephrology, cardiology, pulmonology, neurology, psychiatry, nurs-
ing, nutrition, clinical research and the amyloid program. The eval-
uation involves 3 days of visits which assess organ involvement,
performance status, support network including their ability to phys-
ically and emotionally adhere to an outpatient treatment program as
well as to post-transplant follow-up, and candidacy for a research
protocol. Weekly meetings are held to discuss evaluation results
and determine eligibility before a patient can be scheduled. Once
treatment begins, daily rounds, including toxicity evaluations, phys-
ical exams, medication review and reinforcement of the treatment
plan are conducted. Oral and written instructions are provided re-
garding expected toxicities, symptom management and emergency
contacts. Prophylactic treatment with antiemetic, antibacterial, anti-
viral, antifungal and growth factors are used. Themost common rea-
son for hospital admission is febrile neutropenia. Severe nausea,
vomiting, diarrhea, dehydration may also necessitate hospitalization.
CPs and SOPs were developed early on in the program and are
adhered to with a mechanism to document any deviations. CPs are
reviewed annually for revisions based on current peer-reviewed liter-
ature and program experience. Educational short courses are held
regularly for staff to insure adherence to CPs and SOPs. In summary,
outpatient HDM/SCT is a feasible treatment option for patients
with AL amyloidosis, provided treatment is conducted in an experi-
enced center.102
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Background: Approximately 20% of patients with multiple my-
eloma (MM) have renal failure at diagnosis, and about 5% are di-
alysis-dependent. These patients may potentially benefit from
high-dose chemotherapy and autologous hematopoietic stem cell
transplantation (auto SCT). However, many of these patients are
considered ineligible for auto SCT due to concerns about in-
creased treatment-related toxicity. We evaluated the outcome of
46 patient with MM and renal failure, defined as serum creatinine
.2 mg/dl sustained for .1 month, who received auto SCT at our
institution.
Methods: Forty-six patients with a median age of 56 years (range:
29–72) received auto SCT between September 1997 and August
2006. Median serum creatinine and creatinine clearance (CrCl) at
auto SCT were 2.9 mg/dl (range 2.0 – 12.5) and 33 ml/min (range
8.7 – 63), respectively. Ten patients (22%) were dialysis-dependent.
Results: Median follow up in surviving patients was 34 months
(range 5–81). Complete (CR) and partial responses (PR) were seen
in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall
response rate of 75%. Two patients (4%) died within 100 days of
auto SCT. Grade 2–4 Non-hematological adverse events were
seen in 18 patients (39%) and included cardiac arrythmias, pulmo-
nary edema, hyperbilirubinemia. Median progression-free (PFS)
was 22.8 months and median overall survival OS has not yet been
reached. Kaplan-Meier estimates of 3-year PFS and OS were 36%
and 64%, respectively. Thirty patients (62.5%) are still alive after
a median follow up of 34 months, and 18 patients (39%) are alive
and progression-free. Significant improvement in renal function, de-
fined as an increase in GFR by 25% above baseline, was seen in 17
patients (37%). None of the 10 dialysis-dependent patients became
dialysis independent. A pre-transplant creatinine level of $3mg/dlwas associated with a significantly shorter overall survival (p 5
0.05, HR 2.8).
Conclusions: Auto SCT was safe and feasible in selected patients
with MM and renal failure, and was associated with a significant im-
provement in renal function in approximately one-third of the trans-
planted patients.103
CYTOREDUCTIVE REGIMEN CONTAINING RANIMUSTINE (MCNU), CAR-
BOPLATIN, ETOPOSIDE AND CYCLOPHOSPHAMIDE (MCEC) BEFORE AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(PBSCT) FOR RELAPSED OR REFRACTORY LYMPHOMA
Asakura, Y., Tanosaki, R., Kim, S.-W., Azuma, T., Kurosawa, S.,
Yakushijin, K., Maruyama, D., Mori, S.-i., Fukuda, T., Watanabe, T.,
Kobayashi, Y., Tobinai, K., Takaue, Y. National Cancer Center Hospital,
Chuo-ku, Tokyo, Japan
MCNU, a derivative of nitrosourea that was developed in Japan,
shows good penetration into CSF and might be expected to decrease
CNS relapse of lymphoid malignancies when used before transplan-
tation. However, its feasibility and efficacy have not been extensively
analyzed in adult patients with lymphoma. We retrospectively eval-
uated anMCEC regimen which consisted ofMCNU (200mg/m2 on
days -8 and -3), carboplatin (300 mg/m2 on days -7 through -4), eto-
poside (500 mg/m2 on days -6 through -4) and cyclophosphamide
(50 mg/kg on days -3 and -2) in 68 patients with lymphoma (median
age, 48 yr: range, 20–65 yr) who underwent autologous PBSCT at
our institution between Jan. 1999 and Feb. 2008. The diagnosis in-
cludedDLBCL (N5 33), FL (14), including 6 transformants, T-cell
lymphoma (12), and HL (9). The median time from diagnosis to
PBSCTwas 20 months (4–198 mo), and the median number of prior
chemotherapy regimens was 3 (2–7). 97% had ECOG PS\ 2, 41%
had prior XRT, 4% had bulky disease, 62% had stage III-IV disease,
28% had IPI at relapse of H/H-I. The disease status at PBSCT was
1st CR/PR in 15%, $ 2nd CR/PR in 72%, and NC/PD in 13%.
Grade (G) 4 non-hematological toxicities (CTCAE ver. 3.0) in-
cluded elevated transaminase (1), hyponatremia (1) and hypokalemia
(1). GI and CNS toxicities consisted of G3 mucositis (10), G3 diar-
rhea (27) and G2 seizure (1). There were no G4 cardiac, pulmonary
or renal toxicities except for one who died of treatment-related
MOF. The cumulative incidence of relapse at 2 yrs was 49 %. Of
33 relapses, 2 occurred newly in the CNS without any previous his-
tory.With a median follow-up of 24 months (3–80) after PBSCT for
surviving patients, the 2-yr OS and PFS were 68% (95% CI 55–
81%) and 50% (95% CI 38–63%), respectively. In univariate analy-
ses, T-cell phenotype (p\ 0.01), bulky disease (p\ 0.01), disease
status other than CR/PR (p\ 0.01), stage III-IV (P 5 0.03), IPI
(H/H-I, p \ 0.01) and treatment without rituximab (p \ 0.01)
were unfavorably associated with OS. Multivariate analysis con-
firmed that T-cell phenotype (HR 1.85; 95% CI 0.85–2.86, p \
0.01), bulky disease (HR 3.02; 95% CI 1.26–4.79, p\0.01), disease
status (HR 1.95; 95% CI 0.89–3.01, p\ 0.01), IPI (HR 2.66; 95%
CI 1.19–4.14, p \ 0.01) and treatment without rituximab (HR
4.12; 95% CI 1.14–7.10, p \ 0.01) were unfavorably associated
with OS. The results suggested that autologous PBSCT with the
MCEC regimen is a feasible and effective treatment option for re-
lapsed/refractory lymphoma.104
TIMING OF HIGH DOSE MELPHALAN (HDM) AND OUTCOMES FOR AU-
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HDM is the most widely used preparative regimen for ASCT in
MM. The timing of HDM prior to transplantation has varied be-
tween studies. HDM is given on day –2 (2 days prior to stem cell
infusion) in some and on day –1 in others. At our institution,
HDM was initially given on day -2. Considering Melphalan un-
dergoes rapid hydrolysis in plasma with a short half-life in the or-
der of 60–90 minutes, administration on day -1 seemed feasible and
